Background-This study examines the effects of nicorandil, a K ϩ channel opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS). 
R ecent studies have identified 5 forms of the congenital long-QT syndrome (LQTS) caused by mutations in ion channel genes located on chromosomes 3, 7, 11, and 21. [1] [2] [3] Mutations in KCNQ1 and KCNE1 are responsible for defects in the slowly activating component of the delayed rectifier potassium current (I Ks ), which underlies the LQT1 and LQT5 forms of the LQTS, whereas mutations in HERG and KCNE2 are responsible for defects in the rapidly activating component of the delayed rectifier potassium current (I Kr ) responsible for LQT2 and LQT6. Mutations in SCN5A alter the function of the sodium channel (I Na ) responsible for LQT3.
Linkage of gene mutations to ion channel dysfunction is a first step in the formulation of a gene-specific approach to therapy in congenital LQTS. Identification of agents that exert differential actions in the various genotypes of LQTS is a next step. Schwartz and coworkers 4 demonstrated that the sodium channel blocker mexiletine is more effective in shortening the QT interval in LQT3 patients with sodium channel defect than in either LQT1 or LQT2 patients with potassium channel defects. Compton et al 5 showed that potassium infusion abbreviated the QT interval in LQT2 patients with an I Kr defect. More recently, Shimizu and coworkers 6 reported that nicorandil, a K ϩ channel opener, abbreviated the QT interval and monophasic action potential duration prolonged by epinephrine infusion in LQT1 patients with the I Ks defect. However, shortening of the QT interval by these interventions is not necessarily congruent with their efficacy to decrease arrhythmic risk and sudden cardiac death.
We have developed an arterially perfused canine left ventricular wedge preparation in which we are able to simultaneously record transmembrane action potentials from epicardial, midmyocardial (M), and endocardial sites along the transmural surface using floating glass microelectrodes together with a transmural pseudo-ECG. [7] [8] [9] [10] [11] [12] [13] [14] The wedge is capable of developing and sustaining a variety of arrhyth-mias, including torsade de pointes (TdP). 9, [11] [12] [13] [14] In the present study, we use this preparation to examine the effect of nicorandil, a K ϩ channel opener, to decrease transmural dispersion of repolarization (TDR) and suppress TdP under control conditions as well as conditions mimicking the LQT1, LQT2, and LQT3 forms of congenital LQTS.
Methods

Arterially Perfused Wedge of Canine Left Ventricle
The methods used for isolation, perfusion, and recording of transmembrane activity from the arterially perfused canine left ventricular wedge preparation, as well as the viability and electrical stability of the preparation, are detailed in previous studies. [7] [8] [9] [10] [11] [12] [13] [14] Time controls have demonstrated the electrical stability of the wedge preparations for a period of Ͼ6 hours.
Briefly, dogs weighing 20 to 25 kg were anticoagulated with heparin and anesthetized with pentobarbital (30 to 35 mg/kg IV). The chest was opened via a left thoracotomy, and the heart was excised and placed in a cardioplegic solution consisting of cold (4°C) or room-temperature Tyrode's solution containing 8.
Transmural wedges with dimensions of Ϸ2ϫ1.5ϫ0.9 to 3ϫ2ϫ1.5 cm were dissected from the left ventricle. The tissue was cannulated via a small (diameter Ϸ100 m) native branch of the left anterior descending coronary artery and perfused with cardioplegic solution. Unperfused tissue, readily identified by its maintained red appearance (erythrocytes not washed away), was carefully removed with a razor blade. The preparation was then placed in a small tissue bath and arterially perfused with Tyrode's solution of the following composition (mmol/L): NaCl 129, KCl 4, NaH 2 PO 4 0.9, NaHCO 3 20, CaCl 2 1.8, MgSO 4 0.5, and glucose 5.5, buffered with 95% O 2 and 5% CO 2 (37Ϯ1°C). The perfusate was delivered to the artery by a roller pump (Cole Parmer Instrument Co). Perfusion pressure was monitored with a pressure transducer (World Precision Instruments, Inc) and maintained between 40 and 50 mm Hg by adjustment of the perfusion flow rate.
Recordings of a Transmural ECG and Transmembrane Action Potentials
The ventricular wedges were stimulated with bipolar silver electrodes insulated except at the tips and applied to the endocardial surface (S 1 ). A transmural ECG was recorded by use of 3 mol/L KCl-agar electrodes (1.1 mm ID). The electrodes were placed in the Tyrode's solution bathing the preparation, 1.0 to 1.5 cm from the epicardial and endocardial surfaces of the preparation, along the same vector as the transmembrane recordings (epicardium, ϩ pole). The electrical field of the preparation as a whole was measured with this technique. Thus, the ECG registration represents a pseudo-ECG of that part of the left ventricle. To differentiate it from local electrogram activity, we refer to it as an ECG in the remainder of the text.
Transmembrane action potentials were recorded simultaneously from the epicardial, M, and endocardial sites by use of 3 to 4 separate intracellular floating microelectrodes (DC resistance, 10 to 20 M⍀; 2.7 mol/L KCl). Epicardial and endocardial action potentials were recorded from the epicardial and endocardial surfaces of the preparations at positions approximating the transmural axis of the ECG recording. M-cell action potentials were recorded at the site along the same axis at which action potential duration (APD) was longest. All amplified signals were digitized, stored on magnetic media and WORM-CD, and analyzed with Spike 2 (Cambridge Electronic Design).
Study Protocols
The I Ks blocker chromanol 293B (30 mol/L) was used to create a model of LQT1, 9,14 and isoproterenol (50 to 100 nmol/L) was used to mimic increased ␤-adrenergic tone. The I Kr blocker d-sotalol (100 mol/L) was used to create a model that mimics LQT2. 8, 13, 14 ATX-II (20 nmol/L), an agent that augments late I Na , was used to mimic LQT3. 8, [12] [13] [14] The validity of these pharmacological models as surrogates for the congenital syndromes has been demonstrated in myocyte, 15 wedge, 8, 9, [11] [12] [13] [14] and in vivo studies. 16, 17 We examined (1) the dose-dependent effects of nicorandil (2, 5, 10, and 20 mol/L) on the QT interval, the APD, and the TDR and (2) the effects of nicorandil to suppress the development of spontaneous as well as programmed electrical stimulation (PES)-induced TdP.
Control measurements were generally obtained after 1 hour of equilibration. The chromanol 293B, d-sotalol, and ATX-II data were collected for a period of up to 1 hour starting 1 hour after addition of the respective drug, and nicorandil data were recorded after 20 minutes of exposure to each concentration of drug. In our previous study, dramatic increases of TDR and induction of TdP were seen only in the presence of both isoproterenol and chromanol 293B in the LQT1 model. 9 Therefore, isoproterenol was infused both in the presence of 293B and after each dose of nicorandil, and isoproterenol data were collected at 2 minutes after addition of isoproterenol, approximating the maximal influence of the catecholamine.
APD was measured at 90% repolarization (APD 90 ). TDR was defined as the difference between the longest and the shortest repolarization times (activation time plus APD 90 ) of transmembrane action potentials recorded across the wall (typically, M-cell minus epicardial repolarization time). The QT interval was defined as the time between QRS onset and the point at which the final downslope of the T wave crossed the baseline. In all figures, a graphic correlation of transmembrane and ECG activity was achieved by dropping a dotted line from the point of full repolarization of each action potential (APD 100 approximated by eye) to the ECG trace.
The development of spontaneous and PES-induced TdP was assessed in the absence of any drugs (control conditions); in the presence of chromanol 293B with or without isoproterenol, d-sotalol, or ATX-II; and after the further addition of nicorandil (2, 5, 10, and 20 mol/L). PES-induced arrhythmias were evaluated by use of single extrastimuli (S 2 ) applied to the epicardial surface of the wedge. The vulnerable window was defined as the range of S 1 -S 2 intervals during which a single S 2 could induce TdP.
Statistics
Statistical analysis of the data was performed with a Student's t test for paired data or ANOVA coupled with Scheffé's test, as appropriate. Data are expressed as meanϮSD values, except for those shown in the figures, which are expressed as meanϮSEM values. Significance was defined as a value of PϽ0.05.
Results
Effect of Chromanol 293B؎Isoproterenol, d-Sotalol, and ATX-II on QT Interval, APD, and TDR
The Table shows Figure 2B ). An incomplete reversal (Յ50%) was observed in LQT3 preparations with both large and small TDR. Figure 5 graphically illustrates the normalized doseresponse relationships (semilog scale) of nicorandil on the APD 90 of the M ( Figure 5A ) and epicardial ( Figure 5B ) cells, the QT interval ( Figure 5C ), and TDR ( Figure 5D ) in the 3 models. Nicorandil 20 mol/L totally reversed the effect of the drugs in LQT1 and LQT2 but reversed only 50% of the effect of ATX-II (LQT3).
Effect of Nicorandil on TdP in the LQT1, LQT2, and LQT3 Models
Under control conditions and in the presence of chromanol 293B alone, neither spontaneous nor PES-induced TdP was observed other than an occasional extrasystole. Spontaneous TdP developed in 1 of 6 LQT1ϩisoproterenol, 2 of 6 LQT2, and 3 of 6 LQT3 preparations ( Figures 6A and 7) . A single extrastimulus reproducibly induced TdP in 3 of 6 LQT1ϩisoproterenol, 3 of 6 LQT2, and 5 of 6 LQT3 preparations ( Figures 6B and 7) . In the LQT1 and LQT2 models, relatively low concentrations of nicorandil (5 mol/L) partially suppressed both spontaneous and PESinduced TdP and reduced the vulnerable window (LQT1ϩisoproterenol, 32Ϯ9 to 13Ϯ5 ms; LQT2, 33Ϯ10 to 17Ϯ5 ms) in conjunction with a decrease in TDR (LQT1ϩisoproterenol, 84Ϯ17 to 68Ϯ19 ms; LQT2, 74Ϯ9 to 55Ϯ11 ms). Higher concentrations of nicorandil (10 to 20 mol/L) completely suppressed spontaneous and PESinduced TdP in these models ( Figure 7A and 7B) . In contrast, 5 mol/L nicorandil did not prevent TdP or reduce the vulnerable window (81Ϯ27 to 78Ϯ29 ms) and TDR (123Ϯ16 to 110Ϯ24 ms) in the LQT3 model. Even the highest concentration of nicorandil (20 mol/L) failed to totally suppress TdP in this model ( Figure 7C ).
Discussion Differential Effect of a K ؉ Channel Opener on Repolarization in LQT1, LQT2, and LQT3 Syndromes
LQTS is a hereditary disorder characterized by pathophysiological prolongation of the QT interval, polymorphic ventricular tachycardia (TdP), syncope, and sudden cardiac death. 18 -20 Several clinical studies have presented evidence in support of gene-specific therapy in LQTS. 4 -6 However, previous studies involving canine wedge preparations have shown that sodium channel block with mexiletine is effective in decreasing TDR and in suppressing TdP equally in the 3 syndromes, even though abbreviation of the QT interval is more pronounced in LQT3 than in either LQT1 or LQT2. 8, 9 The results suggested that an abbreviation of the QT interval by specific interventions is not necessarily consistent with their effectiveness in reducing arrhythmic risk and that reduction of TDR is a more reliable marker. 
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In the present study, nicorandil was found to be much more effective in preventing TdP in LQT1 and LQT2 than in LQT3. On a percentage basis, nicorandil-induced QT abbreviation and TDR reduction was greater in LQT1 and LQT2. On an absolute basis, the drug-induced QT abbreviation and TDR reduction were similar in the 3 models. In the case of LQT1 and LQT2 but not LQT3, modest concentrations of nicorandil were often able to reduce TDR below the level necessary for the development of TdP (70 to 80 ms). Thus, the key to the effectiveness of nicorandil in LQT1 and LQT2 appears to be the ability of the drug to diminish the width of the vulnerable window created by the TDR. These findings suggest that K ϩ channel openers may be of therapeutic value in LQT1 and LQT2 but perhaps less so in LQT3.
The ionic basis for the differential effects of the K ϩ channel opener in the 3 forms of congenital LQTS may be due to differences in input resistance that result from loss versus gain of ion channel function. The loss of function in LQT1 and LQT2 (reduced I Ks and I Kr ) results in an increase in membrane resistance, which makes it easier for additional current from any source to modulate membrane potential at the level of the plateau. The opposite is true in LQT3. A smaller membrane resistance is encountered in LQT3 because of a gain of function (augmented late I Na ). As a consequence, a further increase in net outward current, such as with I K-ATP activation, is expected to have a relatively small influence on the plateau to abbreviate APD. Conversely, because mem- brane resistance is increased in LQT1 and LQT2, an increase in I K-ATP is expected to produce greater modulation of the plateau, resulting in a greater abbreviation of APD.
The extent to which our pharmacological models mimic the 3 forms of congenital LQTS is difficult to quantify and is subject to modulation by a number of factors, including sympathetic activity. These models have been shown to mimic their clinical counterparts with respect to the ECG signature, rate dependence of QT interval, and response to a variety of drugs. Exceptions to these rules are encountered in the wedge model as they are in the clinic. It is important to keep in mind that individual mutations in KCNQ1, HERG, or SCN5A can cause quantitatively different changes in ion channel characteristics as well as differences in modulation by extrinsic forces. The various mutations responsible for the LQTS phenotype are similar only in their ability to qualitatively reduce or augment function. Thus, qualitatively, the pharmacological models represent reasonable surrogates for both congenital and acquired LQTS.
Effect of a K ؉ Channel Opener on TdP
TdP is an atypical polymorphic ventricular arrhythmia most often associated with QT prolongation in both congenital and acquired forms of LQTS. Recent in vivo studies from El-Sherif et al 16 and Vos and coworkers, 17 perfused wedge studies from our group, 7 simulation studies, 21 and clinical observations using monophasic action potential recordings 6, 22 present evidence in support of the hypothesis that an early afterdepolarization (EAD)-induced triggered activity initiates TdP but that the arrhythmia is maintained by a reentrant mechanism. Our previous studies have demonstrated that sodium channel block with mexiletine suppresses TdP by decreasing TDR in the LQT1, LQT2, and LQT3 syndromes. 8, 9 Similarly, in the present study, nicorandil reduced the vulnerable period for induction of TdP by reducing TDR. When TDR was not reduced below the lower limit of the vulnerable window (TDRϾ70 to 80 ms), spontaneous and stimulation-induced TdP was not suppressed, providing further support for reentry as the basis for the maintenance of TdP. Nicorandil as well as 2 other I K-ATP openers, pinacidil and cromakalim, are known to shorten APD and to suppress EADs induced by cesium chloride, [23] [24] [25] clofilium, 26 or Bay K 8644. 27 Recent clinical studies that used monophasic action potential recordings have reported the effect of nicorandil to abolish EADs. 6, 28 Thus, I K-ATP openers may prevent spontaneous TdP by suppressing the EAD-induced triggered activity responsible for the initiating premature beat.
A problem with K ϩ channel openers is that they can cause a drop in blood pressure and elicit reflex sympathetic activity that may be arrhythmogenic in LQTS. Nicorandil is unique among K ϩ channel openers because it exerts less of a hypotensive effect than other K ϩ channel openers, including cromakalim and pinacidil. 29 The present study examines the dose-dependent effects of nicorandil over a concentration range of 2 to 20 mol/L. Oral dosing of nicorandil leads to blood levels in the range of 0.2 to 0.3 mol/L, whereas intravenous injection can raise plasma levels to 4 mol/L. Although we must exercise great caution in the interpretation of these findings, the data thus far available suggest that intravenous but not orally administered nicorandil may be of therapeutic value in suppressing repetitive episodes of TdP in patients with LQT1 and LQT2 syndromes but less so in those with LQT3. 30 
